Encrypted login | home

Program Information

The Imaging and Radiation Oncology Core (IROC) Cooperatives Activities Supporting the NCI's National Clinical Trial Network

D Followill

D Followill1*, J Galvin2 , J Michalski3 , M Rosen4 , T FitzGerald5 , M Knopp6 , (1) UT MD Anderson Cancer Center, Houston, TX, (2) Thomas Jefferson University Hospital, Newtown, PA, (3) Washington University in St. Louis, St. Louis, MO, (4) University of Pennsylvania Medical Center, Philadelphia, PA, (5) University of Massachusetts Medical School, Lincoln, RI, (6) The Ohio State University, Columbus, OH


SU-F-T-237 (Sunday, July 31, 2016) 3:00 PM - 6:00 PM Room: Exhibit Hall

Purpose:The Imaging and Radiation Oncology Core (IROC) Cooperative has been active for the past two years supporting the National Clinical Trial Network and the details of that support are reported.

Methods:There are six QA centers (Houston, Ohio, Philadelphia-RT, Philadelphia-DI, Rhode Island, St. Louis) providing an integrated RT and DI quality control program in support of the NCI’s clinical trials. The QA Center’s efforts are focused on assuring high quality data for clinical trials designed to improve the clinical outcomes for cancer patients worldwide. This program is administered through five core services: site qualification, trial design support, credentialing, data management, and case review.

Results:IROC currently provides core support for 172 NCTN trials with RT, DI and RT/DI components. Many of these trials were legacy trial from the previous cooperative group program. IROC monitors nearly 1800 RT photon and 20 proton institutions. Over 28,000 beams outputs were monitored with 8% of the sites requiring repeat audits due to beam out of criteria. As part of credentialing, 950 QA phantoms have been irradiated, 515 imaging modalities evaluated and almost 4000 credentialing letters have been issued. In just year 2, 5290 RT and 4934 DI patient datasets were received (many using TRIAD) by IROC QA Centers to be prepared for review. During the past 2 years, a total of 6300 RT cases and 19,000 DI image sets were reviewed by IROC technical staff. To date, IROC has published 36 manuscripts.

Conclusion:The QA services provided by IROC are numerous and are continually being evaluated for effectiveness, harmonized across all NCTN Groups and administered in an efficient and timely manner to enhance accurate and per protocol trial data submission. These efforts increase each NCTN Group’s ability to derive meaningful outcomes from their clinical trials.

Funding Support, Disclosures, and Conflict of Interest: This work was supported by DHHS NIH grant 5U24CA180803

Contact Email: